# Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam

> **NCT04182191** · PHASE4 · COMPLETED · sponsor: **University of Sao Paulo** · enrollment: 89 (actual)

## Conditions studied

- Molar, Third
- Pain

## Interventions

- **DRUG:** Tenoxicam

## Key facts

- **NCT ID:** NCT04182191
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-11-01
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2019-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182191, "Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04182191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*